# US 6,730,269 B2 · Nanoparticles having oligonucleotides attached thereto and uses therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,269 B2
- Document ID: US6730269B2
- Status: Granted
- Kind: B2
- Application number: 09/976,617
- Filed: 2001-10-12
- Published: 2002-09-26
- Granted: 2004-05-04
- Earliest claimed: 1996-07-29
- Assignees: Nanosphere, Inc.
- Inventors: Chad A. Mirkin; Robert L. Letsinger; Robert C. Mucic; James J. Storhoff; Robert Elghanian; Thomas A. Taton
- Web page: https://patentgrep.com/patent/US6730269B2

## CPC

- C07H 21/00: Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- B82Y 15/00: Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
- B82Y 30/00: Nanotechnology for materials or surface science, e.g. nanocomposites
- C12Q 1/6813: Hybridisation assays
- C12Q 1/6816: characterised by the detection means (C12Q1/6804 takes precedence)
- C12Q 1/6818: involving interaction of two or more labels, e.g. resonant energy transfer
- C12Q 1/6825: Nucleic acid detection involving sensors
- C12Q 1/6827: for detection of mutation or polymorphism
- C12Q 1/6834: Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q 1/6837: using probe arrays or probe chips (C12Q1/6874 takes precedence)
- C12Q 1/6839: Triple helix formation or other higher order conformations in hybridisation assays
- B01J 2219/00274: Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J 2219/005: Beads
- B01J 2219/00585: Parallel processes
- B01J 2219/00596: Solid-phase processes
- B01J 2219/00603: Making arrays on substantially continuous surfaces
- B01J 2219/00648: by the use of solid beads
- B01J 2219/00653: the compounds being bound to electrodes embedded in or on the solid supports
- B01J 2219/00659: Two-dimensional arrays
- B01J 2219/00702: Processes involving means for analysing and characterising the products
- B01J 2219/00722: Nucleotides
- B82B 1/00: Nanostructures formed by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
- C07B 2200/11: Compounds covalently bound to a solid support
- C40B 40/06: Libraries containing nucleotides or polynucleotides, or derivatives thereof
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- Y10S 977/924: using nanostructure as support of dna analysis
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- B01J: CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B82B: NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The invention provides methods of detecting a nucleic acid. The methods comprise contacting the nucleic acid with one or more types of particles having oligonucleotides attached thereto. In one embodiment of the method, the oligonucleotides are attached to nanoparticles and have sequences complementary to portions of the sequence of the nucleic acid. A detectable change (preferably a color change) is brought about as a result of the hybridization of the oligonucleotides on the nanoparticles to the nucleic acid. The invention also provides compositions and kits comprising particles. The invention further provides methods of synthesizing unique nanoparticle-oligonucleotide conjugates, the conjugates produced by the methods, and methods of using the conjugates. In addition, the invention provides nanomaterials and nanostructures comprising nanoparticles and methods of nanofabrication utilizing nanoparticles. Finally, the invention provides a method of separating a selected nucleic acid from other nucleic acids.

## Claims

### Claim 1

A method of nanofabrication comprising
providing at least one type of linking oligonucleotide having a selected sequence, the sequence of each type of linking oligonucleotide having at least two portions;
providing one or more types of nanoparticles having oligonucleotides bound thereto, wherein the oligonucleotides are present on a surface of the nanoparticles at a surface density of at least 10 picomoles/cm2, at least some of the oligonucleotides on each type of nanoparticles comprise at least one type of recognition oligonucleotides, each type of recognition oligonucleotides comprises a spacer portion and a recognition portion, the spacer portion being designed so that it is bound to the nanoparticles, the recognition portion comprises a sequence complementary to at least a portion of the sequence of a specific type of linking oligonucleotide; and
contacting the linking oligonucleotides and nanoparticles under conditions effective to allow hybridization of at least a portion of the oligonucleotides on the nanoparticles to the linking oligonucleotides so that a desired nanomaterial or nanostructure is formed.

### Claim 2 (depends on 1)

The method of claim 1 wherein the linking oligonucleotide is single-stranded.

### Claim 3 (depends on 1)

The method of claim 1 wherein the linking oligonucleotide is double-stranded and has overhanging ends.

### Claim 4 (depends on 1)

The method of claim 1 wherein the linking oligonucleotide is a triple-stranded oligonucleotide connector.

### Claim 5 (depends on 1)

The method of claim 1 wherein the linking oligonucleotide comprises a peptide nucleic acid chain.

### Claim 6

A method of nanofabrication comprising:
providing at least two types of nanoparticles having oligonucleotides bound thereto wherein the oligonucleotides are present on a surface of the nanoparticles at a surface density of at least 10 picomoles/cm2, wherein at least some of the oligonucleotides on each type of nanoparticles comprise one or more types of recognition oligonucleotides, each type of recognition oligonucleotides comprises a spacer portion and a recognition portion, the spacer portion being designed so that it is bound to the nanoparticles, at least one type of recognition oligonucleotides on a first type of nanoparticles comprises a recognition portion having a sequence complementary to at least a portion of the oligonucleotides on a second type of nanoparticles and at least one type of recognition oligonucleotides on the second type of nanoparticles comprises a recognition portion having a sequence complementary to at least a portion of the oligonucleotides on the first type of nanoparticles; and
contacting the first and second types of nanoparticles under conditions effective to allow hybridization of at least a portion of the oligonucleotides on the nanoparticles to each other so that a desired nanomaterial or nanostructure is formed.

### Claim 7 (depends on 1, 6)

The method of any one of claims 1 or 6 wherein the oligonucleotides are attached to the nanoparticles in a stepwise ageing process comprising (i) contacting the oligonucleotides with the nanoparticles in a first aqueous solution for a period of time sufficient to allow some of the oligonucleotides to bind to the nanoparticles; (ii) adding at least one salt to the first aqueous solution to create a second aqueous solution; and (iii) contacting the oligonucleotides and nanoparticles in the second aqueous solution for an additional period of time to enable additional oligonucleotides to bind to the nanoparticles.

### Claim 8 (depends on 7)

The method of claim 7 wherein the second aqueous solution has an ionic strength sufficient to overcome at least partially the electrostatic attraction or repulsion of the oligonucleotides for the nanoparticles and the electrostatic repulsion of the oligonucleotides to each other.

### Claim 9 (depends on 7)

The method of claim 7 wherein the oligonucleotides and nanoparticles are contacted in aqueous solution for about 12 to about 24 hours.

### Claim 10 (depends on 7)

The method of claim 7 wherein salt is added to the aqueous solution to form the aqueous salt solution which is buffered at pH 7.0 and which contains about 0.1 M NaCl.

### Claim 11 (depends on 7)

The method of claim 7 wherein the oligonucleotides and nanoparticles are contacted in the aqueous salt solution for an additional 40 hours to increase the density of oligonucleotides bound to the nanoparticles.

### Claim 12 (depends on 10)

The method of claim 10 wherein the salt is added to the first aqueous solution in a single addition.

### Claim 13 (depends on 10)

The method of claim 10 wherein the salt is added gradually to the first aqueous solution over time.

### Claim 14 (depends on 10)

The method of claim 10 wherein the salt is selected from the group consisting of consisting of sodium chloride, magnesium chloride, potassium chloride, ammonium chloride, sodium acetate, ammonium acetate, a combination of two or more of these salts, one of these salts in a phosphate buffer, and a combination of two or more these salts in a phosphate buffer.

### Claim 15 (depends on 14)

The method of claim 14 wherein the salt is sodium chloride in a phosphate buffer.

### Claim 16 (depends on 1, 6)

The method of claim 1 or 6 wherein the oligonucleotides are present on the surface of the nanoparticles at a surface density of at least 15 picomoles/cm2.

### Claim 17 (depends on 16)

The method of claim 16 wherein the oligonucleotides are present on the surface of the nanoparticles at a surface density from about 15 picomoles/cm2 to about 40 picomoles/cm2.

### Claim 18 (depends on 1, 6)

The method of any one of claim 1 or 6 where the nanoparticles are gold metal nanoparticles or semiconductor nanoparticles.

### Claim 19 (depends on 18)

The method of claim 18 wherein the nanoparticles are gold nanoparticles.

### Claim 20 (depends on 18)

The method of claim 18 wherein the semiconductor nanoparticles are made of CdSe/ZnS (core/shell).

### Claim 21 (depends on 1, 6)

The method of any one of claim 1 or 6 wherein the spacer portion has a moiety covalently bound to it, the moiety comprising a functional group through which the spacer portion is bound to the nanoparticles.

### Claim 22 (depends on 1, 6)

The method of any one of claim 1 or 6 wherein the spacer portion comprises at least 10 nucleotides.

### Claim 23 (depends on 22)

The method of claim 22 wherein the spacer portion comprises from about 10 to about 30 nucleotides.

### Claim 24 (depends on 22)

The method of claim 22 wherein the bases of the nucleotides of the spacer portion arc all adenines, all thymines, all cytosines, all uracils or all guanines.

### Claim 25 (depends on 1, 6)

The method of any one of claim 1 or 6 wherein at least some the oligonucleotides bound to the nanoparticles comprise a type of diluent oligonucleotides.

### Claim 26 (depends on 25)

The method of claim 25 wherein the diluent oligonucleotides contain about the same number of nucleotides as are contained in the spacer portions of the recognition oligonucleotides.

### Claim 27 (depends on 26)

The method of claim 26 wherein the sequence of the diluent oligonucleotides is the same as hat of the spacer portions of the recognition oligonucleotides.

### Claim 28 (depends on 1, 6)

The method of any one of claim 1 or 6 wherein the oligonucleotides are bound to the nanoparticles through sulfur linkages.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

A nanomaterial or nanostructure prepared in accordance with any one of claims 1-28.

### Claim 30

A kit comprising
(i) one or more types of linking oligonucleotide having a selected sequence, the sequence of each type of linking oligonucleotide having at least two portions; and
(ii) one or more types of nanoparticles having oligonucleotides bound thereto wherein the oligonucleotides are present on a surface of the nanoparticles at a surface density of at least 10 picomoles/cm2, at least some of the oligonucleotides on each type of nanoparticles comprise at least one type of recognition oligonucleotides, each type of recognition oligonucleotides comprises a spacer portion and a recognition portion, the spacer portion being designed so that it is bound to the nanoparticles, and the recognition portion having a sequence complementary to at least a portion of the sequence of a specific type of linking oligonucleotide.

### Claim 31 (depends on 30)

The kit of claim 30 wherein the linking oligonucleotide is single-stranded.

### Claim 32 (depends on 30)

The kit of claim 30 wherein the linking oligonucleotide is double-stranded and has overhanging ends.

### Claim 33 (depends on 30)

The kit of claim 30 wherein the linking oligonucleotide is a triple-stranded oligonucleotide connector.

### Claim 34 (depends on 30)

The kit of claim 30 wherein the linking oligonucleotide comprises a peptide nucleic acid chain.

### Claim 35 (depends on 30)

The kit of claim 30 wherein the oligonucleotides are attached to the nanoparticles in a stepwise ageing process comprising (i) contacting the oligonucleotides with the nanoparticles in a first aqueous solution for a period of time sufficient to allow some of the oligonucleotides to bind to the nanoparticles; (ii) adding at least one salt to the first aqueous solution to create a second aqueous solution; and (iii) contacting the oligonucleotides and nanoparticles in the second aqueous solution for an additional period of time to enable additional oligonucleotides to bind to the nanoparticles.

### Claim 36 (depends on 35)

The kit of claim 35 wherein the second aqueous solution has an ionic strength sufficient to overcome at least partially the electrostatic attraction or repulsion of the oligonucleotides for the nanoparticles and the electrostatic repulsion of the oligonucleotides to each other.

### Claim 37 (depends on 35)

The kit of claim 35 wherein the oligonucleotides and nanoparticles are contacted in aqueous solution for about 12 to about 24 hours.

### Claim 38 (depends on 35)

The kit of claim 35 wherein salt is added to the first aqueous solution to form the second aqueous solution which is buffered at pH 7.0 and which contains about 0.1 M NaCl.

### Claim 39 (depends on 35)

The kit of claim 35 wherein the oligonucleotides and nanoparticles are contacted in the second aqueous solution for an additional 40 hours to increase the density of oligonucleotides bound to the nanoparticles.

### Claim 40 (depends on 38)

The kit of claim 38 wherein the salt is added to the first aqueous solution in a single addition.

### Claim 41 (depends on 38)

The kit of claim 38 wherein the salt is added gradually to the first aqueous solution over time.

### Claim 42 (depends on 38)

The kit of claim 38 wherein the salt is selected from the group consisting of consisting of sodium chloride, magnesium chloride, potassium chloride, ammonium chloride, sodium acetate, ammonium acetate, a combination of two or more of these salts, one of these salts in a phosphate buffer, and a combination of two or more these salts in a phosphate buffer.

### Claim 43 (depends on 42)

The kit of claim 42 wherein the salt is sodium chloride in a phosphate buffer.

### Claim 44 (depends on 30)

The kit of claim 30 wherein the oligonucleotides are present on the surface of the nanoparticles at a surface density of at least 15 picomoles/cm2.

### Claim 45 (depends on 44)

The kit of claim 44 wherein the oligonucleotides are present on the surface of the nanoparticles at a surface density from about 15 picomoles/cm to about 40 picomoles/cm2.

### Claim 46 (depends on 30)

The kit of claim 30 wherein the nanoparticles are metal nanoparticles or semiconductor nanoparticles.

### Claim 47 (depends on 46)

The kit of claim 46 wherein the nanoparticles are gold nanoparticles.

### Claim 48 (depends on 47)

The kit of claim 47 wherein the semiconductor nanoparticles are made of CdSe/ZnS (core/shell).

### Claim 49 (depends on 30)

The kit of claim 30 wherein the spacer portion has a moiety covalently bound to it, the moiety comprising a functional group through which the spacer portion is bound to the nanoparticles.

### Claim 50 (depends on 30)

The kit of claim 30 wherein the spacer portion comprises at least 10 nuclcotides.

### Claim 51 (depends on 50)

The kit of claim 50 wherein the spacer portion comprises from about 10 to about 30 nucleotides.

### Claim 52 (depends on 50)

The kit of claim 50 wherein the bases of the nucleotides of the spacer portion are all adenines, all thymines, all cytosines, all uracils or all guanines.

### Claim 53 (depends on 50)

The kit of claim 50 wherein the bases of the nucleotides of the spacer portion are all adenines, all thymines, all cytosines, all uracils or all guanines.

### Claim 54 (depends on 30)

The kit of claim 30 wherein at least some the oligonucleotides bound to the nanoparticles comprise a type of diluent oligonucleotides.

### Claim 55 (depends on 54)

The kit of claim 54 wherein the diluent oligonucleotides contain about the same number of nucleotides as are contained in the spacer portions of the recognition oligonucleotides.

### Claim 56 (depends on 54)

The kit of claim 54 wherein the sequence of the diluent oligonucleotides is the same as that of the spacer portions of the recognition oligonucleotides.

### Claim 57 (depends on 30)

The kit of claim 30 wherein the oligonucleotides are bound to the nanoparticles through sulfur linkages.
